Other languages SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
41.44 ^USD	+0.19%		+12.70%	+13.53%

Jul. 01	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
Jul. 01	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Premarket Monday	Jul. 01
Sector Update: Health Care	Jul. 01
SpringWorks Therapeutics Submits New-Drug Application to FDA for Mirdametinib	Jul. 01
Springworks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with Nf1-Pn	Jul. 01
SpringWorks Therapeutics, Inc. Receive Notice of Termination of the Amended and Restated Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd	Jun. 07
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing	Jun. 05
Springworks Therapeutics Insider Sold Shares Worth $1,955,113, According to a Recent SEC Filing	Jun. 05
SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	May. 23
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	May. 02
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	Mar. 04
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	Feb. 27
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	Feb. 06
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	Feb. 02
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Dec. 05
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05
SpringWorks Therapeutics Prices $275 Million Share Offering	Dec. 05
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours	Dec. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Other languages

Filters